Immunohistochemistry Companies

The global immunohistochemistry market is projected to reach USD 5.14 billion by 2030 from USD 3.55 billion in 2025, at a CAGR of 7.6% during the forecast period.

F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), Becton, Dickinson and Company (US), Takara Bio Inc. (Japan), PHC Holdings Corporation (Japan), Enzo Biochem Inc. (US), Sino Biological, Inc. (China), OriGene Technologies, Inc. (US), Cell Signaling Technology, Inc. (US), Bio SB (US), Miltenyi Biotec (Germany), Sakura Finetek (US), EagleBio (US), Biocare Medical LLC (US), Elabscience BioInnovation Inc. (US), Bio-Genex (US), Diagnostic BioSystems Inc. (US), Histo-Line Laboratories (Italy), Rockland Immunochemicals, Inc. (US), and CANDOR Bioscience GmbH (Germany) are the key players in this market.

To know about the assumptions considered for the study download the pdf brochure

These market players have implemented several strategies, including product launches, acquisitions, agreements, collaborations, and expansions, to enhance their positions in the market. For instance, in April 2023, Leica Biosystems, a subsidiary of Danaher Corporation (US), received clearance from the US FDA for its BOND MMR Antibody Panel to detect colorectal cancer. In February 2023, F. Hoffman-La Roche AG (Switzerland) launched the IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody and the ATRX Rabbit Polyclonal Antibody. Danaher’s BenchMark series of instruments utilizes these antibodies to detect brain cancer.

F. Hoffmann-La Roche Ltd (Switzerland) is focused on the development and manufacturing of pharmaceutical and diagnostic products. Within the immunohistochemistry (IHC) sector, the company leverages its Pathology Lab segment to offer a comprehensive portfolio, including its flagship BenchMark and OptiView product lines. Its strategy for market leadership involves consistent innovation, exemplified by recent launches such as the BenchMark ULTRA PLUS system (2022) and the VENTANA ALK (D5F3) CDx Assay (2021). Its robust product pipeline and recent approvals for new antibodies and systems underscore its significant global footprint across key international markets.

Danaher Corporation (US) is a science and technology company that excels in the design, production, and distribution of a diverse array of products and services across the medical, industrial, and commercial domains. Within the specialized field of life sciences and diagnostics, the company asserts its influence through its subsidiary, Leica Biosystems, which is integral to its Anatomical Pathology Diagnostics and Core Lab Diagnostics segments. This division equips laboratories with various crucial tools, including sophisticated chemical and immuno-staining instruments, along with necessary reagents and consumables. Its sustained market leadership is underpinned by a strategy that includes serving a wide customer base, deploying advanced technological solutions, and maintaining comprehensive, high-quality product lines. The company invested USD 1.50 billion in research and development during the 2023 fiscal year. It collaborates with research institutions, universities, and clinicians worldwide to develop better technologies and products. For instance, in June 2024, Leica Biosystem Nussloch GmbH, a subsidiary of Danaher Corporation, partnered with Navinci (Sweden) to advance cancer research using automated in situ proximity ligation assays on the BOND RX Fully Automated Research Stainer. These developments strengthen Danaher's competitive position in the IHC market.

Agilent Technologies, Inc. (US) holds a significant position within the life sciences, diagnostics, and applied chemical industries by delivering application-specific solutions. Its comprehensive offerings, which include instruments, software, services, and consumables, are vital for laboratory operations in a wide variety of sectors, from food and environmental safety to forensics, pharmaceuticals, and energy research. The company actively competes in the immunohistochemistry (IHC) market through its Pathology Solutions division, which is part of the broader Diagnostics and Genomics segment, focusing on products for cancer diagnostics and anatomic pathology. Its growth strategy heavily relies on strategic partnerships to enhance its portfolio. For instance, it partnered with Incyte (US) in January 2024 to develop companion diagnostics for oncology. The company collaborated with Akoya Biosciences (US) in January 2023 on advanced multiplex assays. Moreover, the company is dedicated to broadening its global influence in both developed and developing regions, a commitment underscored by the 2022 launch of a Center of Excellence in India to foster local innovation. This global strategy is supported by an extensive operational presence in key markets worldwide, including the US, UK, China, Germany, Japan, and many others.

Market Ranking

The Immunohistochemistry (IHC) market is moderately consolidated, with key companies holding 85–90% of the global market share. These include Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US). Hoffmann-La Roche has established a strong position through its Pathology Lab segment, offering a comprehensive portfolio of systems and kits like the BenchMark ULTRA and the VENTANA slide scanner. Danaher Corporation contributes via its subsidiary Leica Biosystems, which provides a wide range of immuno-staining instruments and reagents backed by substantial investment in research and development. Agilent Technologies drives its growth through its Pathology Solutions business, focusing on strategic partnerships to develop novel companion diagnostics and multiplex assays.
These companies are driving innovation through significant R&D investment, strategic collaborations, and the consistent launch of new products. Expansion into developing regions, alongside established markets, presents additional growth opportunities. Other players, including smaller specialized firms and startups, hold the remaining 10–15% market share and contribute to product diversity and technological advancement in diagnostics, though their market influence is less pronounced than that of the leading companies.

Related Reports:

Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com